Angela Gifford

Angela Gifford

Auto-generated profile, based on publicly available information

Angela Gifford

Department of Surgery, University of Wisconsin-Madison, 600 Highland Ave, Madison, WI 53792

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2024 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
RWRalph C. Wang
Ralph C. Wang
NDNida F. Degesys
Nida F. Degesys
JFJahan Fahimi
Jahan Fahimi
CJChengshi Jin
Chengshi Jin
EREfrat Rosenthal
Efrat Rosenthal
AGAngela Gifford
Angela Gifford
Frontline health care workers (HCWs) are at high risk of acquiring respiratory viral infections, including influenza and SARS-CoV-2 infections.1,2 During the COVID-19 pandemic, HCWs used personal protective equipment (PPE), such as an N95 filtering facepiece respirator (hereafter, N95), to reduce their risk of becoming infected.3,4 N95s are tight-fitting, disposable respirators designed to prevent aerosolized transmission of viral particles and reduce the likelihood of HCWs acquiring a respiratory viral infection, thus mitigating risk for an essential workforce.4-7 Under nonpandemic circumstances, standard practice is to discard an N95 after close contact with a patient (ie, single use). Prior infectious disease outbreaks and pandemics necessitating N95 conservation prompted the Centers for Disease Control and Prevention to revise its recommendation to include guidelines for both extended use (wearing the same N95 for multiple patient encounters without donning and doffing) and limited reuse (storing an N95 between donnings for no more than 5 donnings), albeit with limited evidence.8,9 Frontline HCWs (including those in emergency departments [EDs]) generally followed these guidelines to conserve PPE during the COVID-19 pandemic, practicing a combination of reuse and extended use of N95s, which we collectively term reuse.10 In practice, patterns of use varied across EDs based on a number of factors, including supply chain and local hospital guidance.

6 May 2025 in Transplantation Proceedings
Verified
Journal Article
Closed access
WVWill Vuyk
Will Vuyk
MBMax Bobholz
Max Bobholz
IEIsla Emmen
Isla Emmen
ALAndrew Lail
Andrew Lail
NMNicholas Minor
Nicholas Minor
JGJacqueline Garonzik-Wang
Jacqueline Garonzik-Wang

16 May 2025 in Journal of the American Geriatrics Society
Verified
Journal Article
Open access
AGAngela Gifford
Angela Gifford
CMChelsea McClellan
Chelsea McClellan
MDMorgan Daven
Morgan Daven
MEMichael Ellenbogen
Michael Ellenbogen
BFBeverly Foster
Beverly Foster
MSManish N. Shah
Manish N. Shah
A core tenant of the Geriatric Emergency care Applied Research Network 2.0—Advancing Dementia Care (GEAR 2.0‐ADC) is the inclusion of community members during all stages of clinical research. As such, we deliberately integrated and supported patient and public involvement in the evaluation and selection of GEAR 2.0‐ADC Pilot Research Grants by developing and adapting traditional grant application review structures, with input from community members, to create the GEAR 2.0‐ADC Community Review Committee approach. Community members, including persons living with dementia, effectively participated in all three rounds of research grant application review and selection, complementing the traditional scientific review process. The structure and flexibility of the GEAR 2.0‐ADC Community Review Committee approach serve as a model for patient and public grant application review involvement with strong potential for applications across grant reviews in other medical specialties.

17 February 2026 in medRxiv
Verified
Preprint
Open access
PDF file
RMRana Mohamed
Rana Mohamed
ASAlex Shipe
Alex Shipe
ALAndrew Lail
Andrew Lail
IEIsla Emmen
Isla Emmen
WVWilliam Vuyk
William Vuyk
JSJeannina Smith
Jeannina Smith
Background: Immunocompromised (IC) individuals are at increased risk for persistent SARS-CoV-2 infections and can develop new viral mutations and lineages not seen in the community. In this case report, a persistent SARS-CoV-2 infection (330 days) in an IC patient is examined for viral mutations and mutations associated with cryptic lineages. Case Presentation: The patient was followed in a longitudinal study examining persistent SARS-CoV-2 in IC patients. The patient provided stool and nasal swab samples biweekly until 28 days post-enrollment, then monthly, and then quarterly after 12 month post enrollment until the participant was no longer positive for SARS-CoV-2. Staff performed RT-qPCR and viral sequencing on the samples. Viral mutations from the XBK lineage were already present in the initial sample. By the end of the infection period, there were 40 fixed consensus changes from XBK of which two mutations were typical for cryptic lineages. Mutations increased steadily over time, with most mutations fixed by day 253, including the cryptic typical mutations. Conclusion: This case demonstrates the potential for persistent SARS-CoV-2 infections to develop mutations and lineages in IC patients and highlights the need for continued SARS-CoV-2 monitoring and treatment in this vulnerable population.

1 January 2026 in Case Reports in Infectious Diseases
Verified
Journal Article
Open access
PDF file
RMRana Mohamed
Rana Mohamed
ASAlex Shipe
Alex Shipe
ALAndrew Lail
Andrew Lail
IEIsla Emmen
Isla Emmen
WVWilliam Vuyk
William Vuyk
JSJeannina Smith
Jeannina Smith
Background: Immunocompromised (IC) individuals are at an increased risk for persistent SARS‐CoV‐2 infections and can develop new viral mutations and lineages not seen in the community. In this case report, a persistent SARS‐CoV‐2 infection (330 days) in an IC patient is examined for viral mutations and mutations associated with cryptic lineages. Case Presentation: The patient was followed up in a longitudinal study examining persistent SARS‐CoV‐2 in IC patients. The patient provided stool and nasal swab samples biweekly until 28 days postenrollment, then monthly, and then quarterly after 12 months post enrollment until the participant was no longer positive for SARS‐CoV‐2. Staff performed RT‐qPCR and viral sequencing on the samples. Viral mutations from the XBK lineage were already present in the initial sample. By the end of the infection period, there were 40 fixed consensus changes from XBK of which two mutations were typical for cryptic lineages. Mutations increased steadily over time, with most mutations fixed by day 253, including the cryptic typical mutations. Conclusion: This case demonstrates the potential for persistent SARS‐CoV‐2 infections to develop mutations and lineages in IC patients and highlights the need for continued SARS‐CoV‐2 monitoring and treatment in this vulnerable population.

23 November 2024 in medRxiv
Verified
Preprint
Open access
PDF file
WVWill Vuyk
Will Vuyk
MBMax Bobholz
Max Bobholz
IEIsla Emmen
Isla Emmen
ALAndrew J Lail
Andrew J Lail
NMNicholas R Minor
Nicholas R Minor
JGJacqueline Garonzik-Wang
Jacqueline Garonzik-Wang
Background: Compared to immunocompetent individuals, those who are immunocompromised, including solid organ transplant (SOT) recipients, have higher SARS-CoV-2-related morbidity and mortality. We determined the duration of SARS-CoV-2 RNA positivity to evaluate viral persistence in SOT recipients. Methods: This study prospectively followed SOT recipients who recently tested positive for SARS-CoV-2. The duration of viral RNA shedding in nasal swabs and stool samples was tracked, and viral genome sequencing was performed where possible. Persistent infection was defined as a positive nucleic acid amplification test (NAAT) for SARS-CoV-2 at 28 days or later after initial infection. This duration was chosen based on the CDC recommendation that immunocompromised individuals isolate for at least 20 days 1 , compared to 10 days for non-immunocompromised individuals. Results: Of 30 SOT recipients, 12 (40%) had SARS-CoV-2 RNA in nasal swabs or stool 28 or more days after the first positive SARS-CoV-2 test. IC-015 had high viral loads (Ct<30) at 28 days, with continued detection for 54 days. Conclusion: In 12 of 30 SOT subjects, SARS-CoV-2 RNA was detected at or beyond 28 days post-detection (dpd), despite vaccination and antibody and/or antiviral treatment in most participants. Three subjects tested positive for SARS-CoV-2 RNA past 50 dpd. The CDC recommendation for 20 days of isolation may be insufficient for SOT recipients. Viral persistence in the setting of host immune suppression, coupled with exposure to antiviral treatments, raises concern about the selection of unusual viral variants. X (twitter) post: Include Visual Abstract and following text: Compared to immunocompetent individuals, those who are immunocompromised, including solid organ transplant (SOT) recipients, have higher SARS-CoV-2-related morbidity and mortality. We determined the duration of SARS-CoV-2 RNA positivity to evaluate viral persistence in SOT recipients. This study prospectively followed SOT recipients who recently tested positive for SARS-CoV-2. The duration of viral RNA shedding in nasal swabs and stool samples was tracked, and viral genome sequencing was performed where possible. Persistent infection was defined as a positive nucleic acid amplification test (NAAT) for SARS-CoV-2 at 28 days or later after initial infection. This duration was chosen based on the CDC recommendation that immunocompromised individuals isolate for at least 20 days 1 , compared to 10 days for non-immunocompromised individuals. In 12 of 30 SOT subjects, SARS-CoV-2 RNA was detected at or beyond 28 days post-detection (dpd), despite vaccination and antibody and/or antiviral treatment in most participants. Three subjects tested positive for SARS-CoV-2 RNA past 50 dpd. The CDC recommendation for 20 days of isolation may be insufficient for SOT recipients. Viral persistence in the setting of host immune suppression, coupled with exposure to antiviral treatments, raises concern about the selection of unusual viral variants. Visual